Pharmacyclics' success with ibrutinib spawns a rare biotech billionaire

Pharmacyclics' ($PCYC) closely watched leukemia drug ibrutinib has been attracting some strong buzz recently. "It's not just promising, it has those unique profiles of looking very efficacious but also really safe," John McCamant, editor of Medical Technology Stock Letter, tells Bloomberg. "That is very rare in cancer drugs." And those kinds of reviews have been pushing its stock price up. So far up, in fact, that Pharmacyclics' CEO Robert Duggan--who controls about 20% of the stock--can now join the exclusive ranks of biotech billionaires. Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.